GAK

Cyclin-G-associated kinase

95,595 patent compounds predicted against GAK, 78,413 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Erlotinib (SCHEMBL8413)	1.00	3/20
Erlotinib (SCHEMBL18563)	0.98	3/20
Erlotinib (SCHEMBL18562)	0.96	3/20
Erlotinib (SCHEMBL33835)	0.89	3/20
SCHEMBL98692	0.92	2/20
SCHEMBL100845	0.80	2/20
SCHEMBL33143	0.79	2/20
SCHEMBL100309	0.77	2/20
SCHEMBL101864	0.74	2/20
SCHEMBL101702	0.71	2/20
SCHEMBL29651	0.71	2/20
SCHEMBL99685	0.71	2/20
SCHEMBL100966	0.70	2/20
SCHEMBL101072	0.70	2/20
SCHEMBL101686	0.70	2/20
SCHEMBL103295	0.68	2/20
Sb-203580 (SCHEMBL95208)	0.67	2/20
SCHEMBL100150	0.66	2/20
SCHEMBL101800	0.66	2/20
SCHEMBL102410	0.66	2/20

Germline variants in GAK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full GAK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to GAK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	PHASE3	RECRUITING
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	PHASE3	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer	PHASE2	COMPLETED
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	PHASE2	COMPLETED
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer	PHASE2	RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.	PHASE2	COMPLETED
Study of AVZO-021 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer	PHASE1	RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy	nan	COMPLETED
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor	nan	UNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GAK binder may also engage these)

Protein	Name	Similarity
Q99KY4	—	1.000	Q99KY4 →
P97874	—	1.000	P97874 →
Q2HJE1	—	0.994	Q2HJE1 →
WDR91	WD repeat-containing protein 91	0.992	landscape →
Q7TMQ7	—	0.992	Q7TMQ7 →
Q27974	—	0.991	Q27974 →
O75061	—	0.991	O75061 →
Q6TEN6	—	0.991	Q6TEN6 →
P70600	—	0.990	P70600 →
Q5RJI5	—	0.990	Q5RJI5 →
Q2I6J0	—	0.990	Q2I6J0 →
O00562	—	0.990	O00562 →
Q8CIP4	—	0.990	Q8CIP4 →
Q8BX57	—	0.990	Q8BX57 →
Q8TDY4	—	0.990	Q8TDY4 →
Q80TZ3	—	0.990	Q80TZ3 →
Q63618	—	0.989	Q63618 →
B2DD29	—	0.989	B2DD29 →
Q6ZPS6	—	0.989	Q6ZPS6 →
P25799	—	0.989	P25799 →
A5PKJ4	—	0.989	A5PKJ4 →
Q80U56	—	0.989	Q80U56 →
Q9WVS8	—	0.989	Q9WVS8 →
Q6ZPE2	—	0.989	Q6ZPE2 →
O15013	—	0.989	O15013 →
Q9D2E2	—	0.989	Q9D2E2 →
P54310	—	0.989	P54310 →
O75064	—	0.989	O75064 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.989	landscape →
Q3ULB5	—	0.989	Q3ULB5 →